Navigation Links
Trovagene to be Added to Russell Microcap Index
Date:6/25/2012

SAN DIEGO, June 25,  2012 /PRNewswire/ -- Trovagene, Inc. (Nasdaq:  TROV), a developer of trans-renal molecular diagnostics, announced that Russell Investments has added Trovagene to the Russell Microcap Index based on Russell Investments annual reconstitution of its family of U.S. indexes finalized after the close of the U.S. markets on June 22, 2012.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

"We are pleased to be included as part of the Russell Microcap Index," said Antonius Schuh, Ph.D., chief executive officer of Trovagene. "We believe that inclusion in the Index, along with our recent Nasdaq listing, will serve to broaden our investor base and increase our stock's liquidity as we continue to grow our business both domestically and globally."

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. In the institutional marketplace, an industry-leading $3.9 trillion in assets currently are benchmarked to them. Russell calculates more than 80,000 benchmarks daily covering approximately 98 percent of the investable market globally, 83 countries and more than 10,000 securities. These investment tools originated from Russell's multi-manager investment business in the early 1980s when the company saw the need for a more objective, market-driven set of benchmarks in order to evaluate outside investment managers.

Total returns data for the Russell Microcap Index and other Russell Indexes is available at http://www.russell.com/indexes/data/US_Equity/Russell_US_Index_returns.asp.

About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.

Trovagene has a dominant patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in CLL (chronic lymphocytic leukemia) patients.

About Russell
Russell Investments (Russell) is a global asset manager and one of only a few firms that offers actively managed, multi-asset portfolios and services that include advice, investments and implementation. Working with institutional investors, financial advisors and individuals, Russell's core capabilities extend across capital markets insights, manager research, Indexes, portfolio implementation and portfolio construction.

Russell has approximately $155 billion in assets under management (as of 3/31/2012) and works with 2,400 institutional clients, more than 580 independent distribution partners and advisors, and individual investors globally. Founded in 1936, Russell is a subsidiary of The Northwestern Mutual Life Insurance Company. 

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2011 and other periodic reports filed with the Securities and Exchange Commission.

Contact:

Trovagene, Inc.
Stephen Zaniboni
Chief Financial Officer
+1 (858) 496-7466
szaniboni@trovagene.com
http://www.trovagene.com


'/>"/>
SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Trovagene, Inc. Announces Full Exercise of Over-Allotment Option by Aegis Capital Corp.
2. Trovagene and Strand Life Sciences Plan Collaboration to Validate and Offer Urine-Based HPV Screening Test in India and South Asia
3. TrovaGene Acquires CLIA - Certified Laboratory
4. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
5. CellerateRX® Added to List of Preferred Products for Golden Living Healthcare Network
6. PTV Interview Exclusive: Revolutionary GSK and J&J Participation in New Index Ventures Fund
7. Survey: Small Medical Practice Confidence Index Rises in 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017  HUYA Bioscience International, (HUYA), ... China,s pharmaceutical innovations, announced today a ... Innovation and Investment Company (referred to as CAS Innovation). ... innovations discovered by leading scientists at CAS to meet ... HUYA is the first company to have recognized ...
(Date:1/18/2017)... Research Future published a half-cooked research report on Global Cancer Diagnostics ... CAGR of 12% during the period 2016 to 2022. ... ... without any control. These abnormal cells have the ability to invade ... spread to other parts of the body through the blood and ...
(Date:1/17/2017)... The Global Implantable Biomaterials Market is ... 7.5% over the next decade to reach approximately ... trends that the market is witnessing include increasing ... transplant surgeries and medical implants and technological advancements. ... into immunomodulatory biomaterials, natural, polymers, hydrogels and ceramics. ...
(Date:1/17/2017)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ... and earnings conference call will be broadcast live over ... a.m. Eastern Time.  A news release detailing the quarterly ... a.m. Eastern Time the morning of the conference call. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
Breaking Biology Technology:
(Date:12/12/2016)... -- Researchers at Trinity College, Dublin, are opening up ... material with Silly Putty. The mixture (known as "G-putty") ... sense pulse, blood pressure, respiration, and even the ... The research team,s findings were published Thursday in ... Due ...
(Date:12/7/2016)... December 7, 2016 BioCatch , the global ... its patent portfolio, which grew to over 40 granted and pending patents. ... , , ... patent entitled " System, Device, and Method Estimating Force Applied ... device makers to forego costly hardware components needed to estimate the force ...
(Date:12/6/2016)... Valencell , the leading innovator in performance biometric ... consecutive year of triple digit growth for its PerformTek ... 360 percent increase in companies who have acquired Valencell ... sales of its wrist and ear Benchmark™ sensor systems, ... hearables for fitness and healthcare applications. ...
Breaking Biology News(10 mins):